Neurology · 2024 · 18 citations · 27 references
MedicineNeurologyNeuroscienceCell TherapyNeural EngineeringNeurorehabilitationMesenchymal Stem Cell TherapyMesenchymal Stromal Cell TherapyMotor RecoveryNeurological RehabilitationNeuroprotectionTraumatic Brain InjuryMesenchymal Stromal Cell ImmunomodulationMotor DeficitsMotor Function DeficitsMotor Function RehabilitationMotor RehabilitationNeurologic DeficitsNeurologic FunctionPrimary Efficacy Endpoints
BACKGROUND AND OBJECTIVES: Traumatic brain injury (TBI) is frequently characterized by chronic motor deficits. Therefore, this clinical trial assessed whether intracranial implantation of allogeneic modified mesenchymal stromal (SB623) cells can improve chronic motor deficits after TBI. METHODS: ) or surgical sham-controlled procedure. The prespecified primary efficacy end point was significantly greater change from baseline of the Fugl-Meyer Motor Scale (FMMS) score, a measure of motor status, for the SB623 pooled vs control arm at 24 weeks. RESULTS: = 0.04), with faster improvement of the FMMS score in SB623-treated groups than in controls at 24 weeks and sustained improvement at 48 weeks. At 48 weeks, improvement of function and activities of daily living (ADL) was greater, but not significantly different in SB623-treated groups vs controls. The incidence of adverse events was equivalent in SB623-treated groups and controls. There were no deaths or withdrawals due to adverse events. DISCUSSION: Intraparenchymal implantation of SB623 cells was safe and significantly improved motor status at 24 weeks in participants with chronic motor deficits after TBI, with continued improvement of function and ADL at 48 weeks. Cell therapy can modify chronic neurologic deficits after TBI. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov Identifier: NCT02416492. Submitted to registry: April 15, 2015. First participant enrolled: July 6, 2016. Available at: classic.clinicaltrials.gov/ct2/show/NCT02416492. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that intracranial implantation of allogeneic stem (SB623) cells in adults with motor deficits from chronic TBI improves motor function at 24 weeks.
27
Guidelines for the Management of Severe Traumatic Brain Injury, Fourth Edition
Nancy Carney, Annette M Totten, Cindy O’Reilly et al. · Neurosurgery · 2016 · 4.3K citations